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Abstract 
Background: Herpes Simplex Virus 2 (HSV-2) is one of the most common sexually transmitted infections (STIs) world-
wide and is a risk factor for the acquisition and transmission of other STIs, including HIV. We determined the preva-
lence and predictors of HSV-2 infection among women screened for a HIV prevention trial in Durban, South Africa. 
Univariate and multivariate logistic and Cox regression models were used to determine the correlates and predictors 
of HSV-2 infection at enrolment and seroconversion during the study respectively.
Results: Prevalence of HSV-2 at screening was 65% and crude incidence was 22.3 per 100 person-years (PY) (95% CI 
20.4–24.3). The HIV seroconversion was significantly higher among those testing positive for HSV-2 at baseline com-
pared to women who were negative [8.7 per 100 person years (PY) versus 5.2 per 100 PY; (p < 0.001)]. In univariate 
analysis, age was determined to be the most significant predictor for HSV-2 diagnosis, while co-infection with syphilis 
was also a significant predictor, while age and co-infection with syphilis remained the two most significant predictors 
of having HSV-2 in multivariate analysis at baseline. Consistent with these results, along with HIV seroconversion, age 
was also identified as a significant predictor for incidence of HSV-2.
Conclusion: Given the unacceptably high prevalence and incidence rates of HSV-2 infection reported here, HSV-2 
and general STI education needs to be reinforced in these communities, with a focus on condom education for 
prevention. HSV-2 has emerged as the most prevalent STI which is most often asymptomatic and unrecognized, and 
which increases women’s risk of acquiring other STIs, including HIV.
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Background
Herpes Simplex Virus 2 (HSV-2) is a chronic, sexu-
ally transmitted infection (STI) which is infectious dur-
ing both its symptomatic and asymptomatic periods [1]. 
This asymptomatic nature of HSV-2 infection assists 
in the spread of the infection in the general population 
[2]. It has been estimated that around 500 million peo-
ple are currently infected with HSV-2 worldwide and that 
approximately 20 million new cases occur each year. In 
European countries, the prevalence of HSV-2 fluctuates 
significantly between countries, varying from approxi-
mately 5% for England and Spain, approximately 20–30% 
for countries such as Germany and Sweden up to 40% for 
Turkey [3]. Considerably higher rates of HSV-2 have been 
observed in sub-Saharan Africa (SSA), with age‐adjusted 
prevalence in adults ranging from 10 to 50% in men and 
30 to 80% in women [4]. Cross sectional studies in SSA 
have shown a prevalence of 5–53% in 13–24  year old 
men and women, respectively [5]. In Uganda, men aged 
15–19  years old had 10% prevalence while 20–24  year 
old men had a 27% prevalence. Ugandan women, showed 
a 35% prevalence among 15–19  year olds versus a 74% 
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prevalence in women aged 20–24 years old [5]. In South 
Africa, studies have shown a 31% prevalence of HSV-2 
in women aged 15–26 [6], while an 84% prevalence was 
shown among female commercial sex workers in the 
province of KwaZulu-Natal (KZN) [7]. The Methods for 
Improving Reproductive Health in Africa (MIRA) dia-
phragm study showed a 73% HSV-2 prevalence in Dur-
ban, with 41% of these women co-infected with Human 
Immunodeficiency Virus (HIV) [8].
Two decades of observational and biological research 
supports the theory that HSV-2 increases the risk of 
HIV-1 acquisition up to four fold [1, 2, 4, 9–11] and 
increases the risk of HIV-1 transmission and infec-
tiousness [4, 9, 12]. A meta-analysis demonstrated that 
HSV-2 seropositivity was associated with a HIV acqui-
sition risk ratio of 2.7 in men and 3.1 in women. HSV-2 
infection has also been associated with increased inci-
dence of other STIs, such as Neisseria gonorrhoeae (NG), 
Treponema pallidum (TP) and Trichomonas vaginalis 
(TV) [11]. This would emphasize the need to test HSV-2 
control strategies as a means to reduce the transmission 
not only of HIV, but also of other STIs [11].
In the KZN province, HIV prevalence among sexually 
active women attending three clinics was estimated to be 
40% [13]. There are many reasons as to why the epidemic 
is spreading uncontrollably in this region; socio-eco-
nomic conditions and specific population dynamics (such 
as patterns of sexual networking, levels of condom use 
and STI infections), are known to be important deter-
minants in the spread of HIV infection [14]. Poor socio-
economic conditions often result in women engaging in 
commercial sex activity. Poverty is also known to result 
in male migrant labour, resulting in men being away from 
their primary sexual partners for extended periods of 
time. This often leads to men having multiple sexual part-
ners [14, 15]. In KZN, a high rate of multiple, concurrent 
and age-discrepant sexual relationships also contribute to 
the spread of HIV in the region. In this largely patriar-
chal society, gender inequality and the inability of women 
to negotiate condom use further contribute to these fac-
tors [14, 15]. Given the relationship between HSV-2 and 
HIV infection, it is important to ascertain the factors that 
put HIV uninfected women at risk of HSV-2 infection in 
regions of high HIV endemicity.
The current study estimates the prevalence and risk 
factors associated with HSV-2 infection among women 
who tested HIV-1 negative in a cohort from an HIV pre-
vention trial. We also estimated the incidence of HIV-1 
and HSV-2 infection among these women during study 
follow-up. These data provide an opportunity to gain fur-
ther insight into the HSV-2 epidemic in the KZN region 
and to inform the design of future HIV/STI prevention 
strategies.
Methods
The Microbicide Development Programme (MDP) 301 
study (2005–2009), was a multicenter, international, dou-
ble-blind, randomized, placebo-controlled trial assess-
ing the safety and efficacy of 0.5 and 2% PRO 2000/5 gels 
for the prevention of vaginally acquired HIV infection 
[16, 17]. Women from six research centers (13 sites) in 
Africa were enrolled. However, since KwaZulu-Natal 
is considered the epicenter of the HIV epidemic, only 
women enrolled at the three Durban sites of the Medi-
cal Research Council (MRC) of South Africa research 
center were considered in this analysis. The protocol was 
approved by the Biomedical Research Ethics Committee 
based at the University of KwaZulu-Natal, the Medicines 
Control Council in South Africa and the US Food and 
Drug Administration. The eligibility criteria included: 
willingness and ability to give informed consent; HIV-
seronegative status at screening; age 18  years or older; 
non-pregnant and not planning to become pregnant for 
the duration of the trial; willing to have regular specu-
lum examinations and urinary pregnancy tests; willing 
to be tested for HIV infection; willingness to use study 
gel as advised; likely to be sexually active; and willing-
ness to receive counseling about condoms. Women 
were excluded if they had any severe clinical, laboratory 
or gynecological abnormalities; had sex  >14 times per 
week, and/or were unlikely to comply with the proto-
col. Women were followed up every 4  weeks for a total 
of 52  weeks. Women were provided with HIV testing 
and counseling, risk reduction education and diagnosis 
and treatment of STIs. Participants diagnosed with cur-
able STIs were invited to bring their male partners to 
the study site for treatment or were provided with refer-
ral cards to access STI treatment at local clinics. Women 
received unrestricted supplies of condoms at all study 
visits and were counseled to use condoms during all sex 
acts. The primary efficacy endpoint of the MDP301 trial 
was HIV-1 infection, using a novel HIV confirmatory 
testing algorithm [18]. Briefly, the algorithm included 
parallel HIV-1 rapid tests at the clinics, with positive 
or discordant tests after enrolment prompting Enzyme 
Immunoassay testing at local laboratories and confir-
mation at a central laboratory in South Africa. The cen-
tral laboratory analysed samples from the study visit at 
which the first positive rapid test result was obtained, in 
addition to previous study visits at which samples were 
obtained. At enrolment and at predefined study vis-
its, additional procedures were carried out according to 
the study schedule. These included a clinical evaluation 
with genital examination, and the collection of addi-
tional specimens for the confirmation of the diagnosis 
of HIV (Enrolment, week 12, week 24, week 40 and week 
52), HSV-2 (Enrolment, week 40 and week 52), syphilis 
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(Enrolment, week 24 and week 52), and other infections 
[N. gonorrhoeae (NG), C. trachomatis (CT), Tricho-
monas vaginalis (TV), bacterial vaginosis and candida] 
at the Enrolment and week 24 visits. HSV-2 was assessed 
using the HerpeSelect 2 IgG ELISA (FOCUS Diagnostics, 
California, USA); Focus index values of ≥3.5 were con-
sidered HSV-2 seropositive [sensitivity of 92% (95% con-
fidence interval (CI) 82–98) and specificity of 91% (95% 
CI 79–98)] [19]. Chlamydial and gonococcal infections 
were assessed using amplicor swabs collected during the 
genital examination by using nucleic acid amplification 
assays (COBAS Amplicor, Roche Molecular Diagnostics, 
Pleasanton, CA, USA). Baseline and confirmatory syphi-
lis testing was conducted on sera using the rapid plasma 
reagin (RPR) (BD Macrovue) and Treponema palladium 
haemagglutination (TPHA) (Fujibrio) methods respec-
tively. Testing for TV was conducted using sterile swabs 
with the In-Pouch-TV test kit [16].
The primary outcome measure of this analysis was 
HSV-2 seropositivity at baseline and the risk factors asso-
ciated with HSV-2 seropositivity. In addition, we assessed 
the risk factors associated with HSV-2 incidence during 
study follow-up. The following variables were considered: 
age (in quartiles), education level (secondary school com-
pleted vs not completed), number of sex acts in last week 
(less than 3 vs more than 3), number of lifetime sexual 
partners (1 partner vs 2 or more partners), employment 
(yes/no), religion (Christian vs other), age at first sex 
act (15 and younger vs 16 and over), contraception use 
[none (reference), hormonal contraception, condoms, 
other (tubal ligation, rhythm method)] and being infected 
with another STI (CT, NG, TV or syphilis). Univariate 
and multivariate logistic regression models were used to 
identify the correlates of HSV-2 infection at screening. 
The multivariate model was constructed using a forward 
stepwise method. We used data driven cut point meth-
ods, such as quartiles, to categorize the continuous age 
variable. Regarding the number of sex acts per week, the 
data driven method was used in such a way that each 
level had enough observations; therefore they will not be 
over- or under-representative of the respective groups. 
Central tendency measures, such as the median, and dis-
persion measures [interquartile ranges (IQRs)] were as 
follows: the median for overall age was 27 (IQR 22–37), 
with the median for HSV-2 negative women being 23 
(IQR 20–29) and the median for HSV-2 positive women 
being 31 (IQR 23-39) (p value for rank test is <0.001); the 
median for number of sex acts per week was three for 
the study population overall (IQR 2–4), with a median 
of 3 (IQR 2–4) for both the HSV-2 positive and negative 
populations (p value for rank test was 0.511). Independ-
ent predictors of HSV-2 infection were assessed using 
Cox proportional hazard regression model. A univariate 
logistic regression was conducted first; risk factors with 
a p value of <0.10 were considered as candidates for the 
multivariate model. We used a forward stepwise tech-
nique to build the final model. All the factors with a p 
value of  <0.05 were retained in the final multivariate 
model. Variables were considered statistically signifi-
cant if p < 0.05. HIV incidence was defined as the time 
from enrolment to seroconversion and/or censoring at 
the end of study follow-up on the basis of a discrete time 
scale determined by a woman’s study visits at 12, 24, 40 
and 52  weeks. The time of seroconversion was defined 
as the time of the initial positive HIV test result. If one 
or more visit between the last negative HIV tests and the 
first positive tests were missed, the time of seroconver-
sion was presumed to be the visit comprising the mid-
point between these two time points. Similarly, the time 
to an HSV-2 positive result after enrolment (tested for at 
weeks 40 and 52) or censoring was used to calculate the 
HSV-2 incidence rate during study follow-up. All analy-
ses were conducted using STATA 12.0 (College Station, 
Texas, USA).
Results
A total of 2236 HIV-negative women were screened and 
enrolled into the MDP 301 trial at clinical research sites 
in Durban, South Africa. The HSV-2 prevalence at base-
line in this cohort of women was 65%. The HIV incidence 
among HSV-2 negative women was 5.2 per 100 person 
years (PY), compared to 8.7 per 100 PY for women that 
were HSV-2 positive at baseline (p < 0.001, log rank test). 
The HSV-2 incidence during study follow-up was 22.3 
per 100 PY (95% CI 20.4–24.3).
Table  1 presents the risk factors for being diagnosed 
with HSV-2 at baseline. In the univariate analysis, the 
risk of HSV-2 infection increased with age [23–27 years 
old odds ratios (OR) 1.76, 95% confidence intervals (CI) 
1.39–2.2; age 28–37 years old OR 3.40, 95% CI 2.67–4.33; 
age  >38  years old OR 6.72, 95% CI 5.06–8.92, respec-
tively]. However, engaging in their first sex act at an age 
younger than 15  years old did not significantly increase 
a woman’s risk of being HSV-2 positive (OR 1.33, 95% 
CI 0.88–2.02), but having two or more lifetime sex part-
ners did significantly increase risk of being HSV-2 posi-
tive (OR 1.27, 95% CI 1.06–1.55). In addition to age, 
being unemployed (OR 1.85, 95% CI 1.43–2.4) or hav-
ing less than high school education (OR 1.78, 95% CI 
1.47–2.14) increased the odds of a woman being HSV-2 
positive at baseline. The type of contraception used by 
women also had an impact on HSV-2 positivity; women 
using “tubal ligation, rhythm, intrauterine devices or 
traditional” forms of contraception were more at risk of 
being HSV-2 positive (OR 1.745, 95% CI 1.09–2.8) than 
women using no contraception, whereas women using 
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hormonal contraception or condoms were less at risk 
of being HSV-2 positive (OR 0.6, 95% CI 0.44–0.89; OR 
0.515, 95% CI 0.36–0.74, respectively) than women using 
no contraception. When considering STIs, infection with 
CT did not increase the odds of being HSV-2 positive, 
while being infected with GC, TV and/or Syphilis did 
(OR 1.89, 95% CI 1.07–3.31, OR 1.51, 95% CI 1.09–2.09 
and OR 4.62, 95% CI 1.97–10.81 respectively); although 
all STIs significantly increased the risk of being HSV-2 
positive at screening in the multivariate analysis. These 
risk factors remained in the multivariate analysis, except 
for religion, number of sex acts per week and hormonal 
contraception (as these were not found to be significant 
in the univariate analysis).
Table  2 presents the predictors of HSV-2 incidence 
during study follow-up. Being over 38  years old was a 
significant predictor for HSV-2 incidence [hazard ratio 
(HR) 1.57 (95% CI 1.23–2.00)], which was sustained in the 
Table 1 Risk factors for being diagnosed with HSV-2 at baseline
CI confidence interval
a Includes tubal ligation, intrauterine devices and traditional methods
* Median (IQR) = 27 (23–37); p value for rank test was < 0.001
** Median (IQR) = 3 (2–4); p value for rank test was 0.511
Variable Overall number (% of group) Univariate analysis Multivariate analysis
N = 2236 Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Age*
 <23 660 (29.5) 1 1
 23–27 484 (21.6) 1.76 (1.39–2.23) 0.001 1.75 (1.37–2.23) 0.001
 28–37 564 (25.2) 3.40 (2.67–4.33) 0.001 3.24 (2.50–4.20) 0.001
 38+ 528 (23.6) 6.72 (5.06–8.92) 0.001 6.08 (4.44–8.32) 0.001
Employed/income
 Yes 1842 (82.4) 1.0 1.0
 No 394 (17.6) 1.85 (1.43–2.36) 0.001 1.43 (1.10–1.87) 0.008
Religion
 Other 1346 (60.2) 1.0 1.0
 Christian 890 (39.8) 1.09 (0.91–1.30) 0.334 – –
Education
 ≥High school 1550 (69.3) 1.0
 <High school 686 (30.7) 1.78 (1.47–2.14) 0.001 1.24 (1.01–1.52) 0.037
Age at first sex act (years)
 >15 2123 (94.9) 1.0
 <15 113 (5.1) 1.33 (0.88–2.02) 0.175 – –
Sex acts per week**
 <3 1282 (57.3) 1.0
 3+ 954 (42.7) 0.99 (0.83–1.18) 0.934 – –
Sexual partners
 1 partner 606 (27.1) 1.0
 2 + partners 1630 (72.9) 1.27 (1.06–1.55) 0.011 – –
STI
 C. trachomatis 244 (10.9) 1.07 (0.81–1.42) 0.624 1.51 (1.11–2.04) 0.007
 N. gonorrhea 71 (3.2) 1.89 (1.07–3.31) 0.027 2.37 (1.31–4.29) 0.004
 Syphilis 56 (2.5) 4.62 (1.97–10.81) 0.001 2.88 (1.20–6.94) 0.018
 T. vaginalis 200 (8.9) 1.51 (1.09–2.09) 0.013 1.50 (1.06–2.12) 0.024
Contraception
 None 185 (8.3) 1.0
 Othera 228 (10.2) 1.75 (1.09–2.81) 0.021 – –
 Hormonal 1196 (53.49) 0.63 (0.44–0.89) 0.008 – –
 Condoms 627 (28.0) 0.52 (0.36–0.74) 0.001 – –
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multivariate analysis [HR 1.71 (95% CI 1.34–2.19)]. Chris-
tianity was also a predictor of HSV-2 incidence in the 
study [HR 1.21 (95% CI 1.01–1.44)], although this was not 
sustained in the multivariate analysis. HIV seroconver-
sion during study follow-up was a significant predictor for 
HSV-2 seroconversion in the univariate [HR 1.71 (95% CI 
1.30–2.24)] and in the multivariate analysis [HR 1.84 (95% 
CI 1.40–2.42)]. Contrary to this, a woman who had an STI 
at baseline or during the study was not at greater risk of 
HSV-2 seroconversion. Similar to our HSV-2 prevalence 
data, women who used “other” methods of contracep-
tion were more at risk of becoming HSV-2 positive dur-
ing the study. Another interesting observation was that 
pregnancy incidence increased a woman’s risk of HSV-2 
infection, both in univariate [HR 1.25 (95% CI 0.93–1.67) 
(p  <  0.133)] and multivariate analysis [HR 1.37 (95% CI 
1.08–1.83) (p < 0.038)], although this was only statistically 
significant in the multivariate analysis.
Table 2 Predictors of incidence of HSV-2
CI confidence interval
a Includes tubal ligation, intrauterine devices and traditional methods
* Median (IQR) = 27 (23–37); p value for rank test was <0.001
Variable Univariate analysis Multivariate analysis
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Age*
 <23 1 1
 23–27 1.18 (0.91–1.54) 0.213 1.21 (0.93–1.58) 0.155
 28–37 1.20 (0.93–1.55) 0.157 1.27 (0.98–1.64) 0.066
 38+ 1.57 (1.23–2.00) <0.001 1.71 (1.34–2.19) <0.001
Employed/income




 Christian 1.21 (1.01–1.44) 0.040 – –
Education
 ≥High school 1
 <High school 1.11 (0.91–1.35) 0.289
Age at first sex act (years)
 >15 1
 <15 1.11 (0.76–1.64) 0.586 – –
STI
 C. trachomatis 1.07 (0.80–1.43) 0.663 – –
 N. gonorrhea 0.76 (0.49–1.18) 0.221 – –
 Syphilis 1.23 (0.66–2.31) 0.510 – –
 T. vaginalis 0.97 (0.71–1.32) 0.835 – –
Contraception
 None 1
 Othera 1.39 (1.08–1.82)) 0.012 – –
 Hormonal 0.86 (0.59–1.25) 0.416 – –
 Condom 0.93 (0.75–1.14) 0.481 – –
Biological factors
 STI (s) baseline 1.04 (0.84–1.29) 0.705 – –
 STI (s) incidence 1.13 (0.90–1.42) 0.314 – –
 HIV incidence 1.71 (1.30–2.24) <0.001 1.84 (1.40–2.42) <0.001
 Pregnancy incidence 1.25 (0.93–1.67) 0.133 1.37 (1.02–1.83) 0.038
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Discussion
Although the HSV-2 prevalence in this study is high, it 
is similar to previous studies from developing countries 
[4, 5] and other South African studies [6, 7, 20, 21]. This 
study was conducted at three urban clinical research 
sites in Durban. Interestingly, the MIRA study, which 
was conducted by the MRC at one rural and one semi-
rural clinical research site in the Durban area 2  years 
prior to the MDP 301 trial, showed a HSV-2 prevalence 
of 73% (median age was 26; IQR 22–34) [8]. This higher 
prevalence in rural/semi-rural areas of Durban could be 
explained by several factors. Since women would have 
less access to jobs in a rural area, they may engage in 
more transactional sex; rural areas have poorer access to 
healthcare, including STI treatment and free condoms; 
and women in rural areas may have had less opportunity 
for education than those women from urban areas, which 
may increase their risk of acquiring HSV-2. The HSV-2 
incidence during study follow-up is staggering and is 
much higher than previously seen in other South African 
studies. The HSV-2 incidence seen in our study compares 
to HSV-2 studies in Kenya and Uganda among female 
sex workers [22]. However, another cohort of Kenyan 
women, who considered themselves to be at high risk of 
HIV infection but were not sex workers, had a similar 
incidence of 22.1 per 100 person-years [23], while a study 
at an STI clinic in Alabama showed women had a HSV-2 
incidence of 20.5 per 100 woman-years [24]. Women 
participating in these HIV prevention trials usually con-
sider themselves at high risk of HIV infection, which 
could explain this high incidence of HSV-2 due to risky 
sexual behavior. The HIV incidence seen in this cohort 
of women was comparable to the HIV incidence among 
HSV-2 positive women in the MIRA trial [20].
Previous analyses of HSV-2 risk factors have shown that 
women whose sexual debut was at an age younger than 
16 were at higher risk of being HSV-2 positive, however 
this was not significant in our cohort [8, 25]. Similar to 
other studies, our results showed that women who had 
not attended high school were at greater risk of having 
acquired HSV-2 [26] and this is possibly due to high school 
attendance influencing the structure of sexual networks 
[27]. Unemployment also put a woman at risk of being 
HSV-2 positive, most likely due to unemployed women 
being dependent on their partner for income, which may 
result in them being unable to negotiate safe sex with part-
ners. Additionally, unemployment can drive women to 
engage in transactional sex. Consistent with other studies, 
the risk of being HSV-2 positive increased with age [25, 
28]. This is most likely due to an increased number of sex-
ual partners and increased years of sexual activity with age 
(both risk factors of HSV-2 infection [25, 26, 28]). Women 
presenting for this clinical trial in Durban, who were 
infected with an STI were significantly more likely to be 
co-infected with HSV-2 than women in the trial that did 
not have an STI, although syphilis showed the greatest risk 
of HSV-2 co-infection. We did note some instances of co-
infections with STIs. Thirty three women were co-infected 
with TV and CT, while 31 women were found to be co-
infected with NG and CT (data not shown). The relation-
ships between HSV-2 and other STIs were expected, since 
it is widely known that there is increased incidence of STIs 
with HSV-2 infection, specifically NG, TV, and T. pal-
lidum infections [11, 25, 28]. However, the same was not 
observed when considering HSV-2 incidence during study 
follow-up. This is not surprising, as women would have 
been treated for their STIs as soon as they were diagnosed, 
according to the study protocol requirements, which could 
explain why having an STI is a risk factor prior to study 
enrolment, but not during the study. The increased risk 
of HSV-2 infection we experienced in pregnant women is 
not surprising, since both are as a result of participating in 
unprotected sex.
Another study looking at HSV-2 in an HIV prevention 
trial in rural/semi-rural Durban sites found that women 
older than 25, having less than high school education, 
being single or cohabiting, being a Christian, young age 
of sexual debut, more than four lifetime partners, giving 
birth to more than one child and co-infection with NG 
put women at an increased risk of being HSV-2 positive 
[8]. Together with this study, our analysis provides us 
with a detailed set of risk factors suited to this region that 
has high HSV-2 and HIV infection.
The use of hormonal contraceptives has recently come 
under the spotlight for possibly increasing the risk of 
HIV-1 acquisition. However, our results showed that 
a woman on hormonal contraception was less likely 
to be HSV-2 infected at baseline in addition to being 
at less risk of HSV-2 infection during study follow-up. 
The link between hormonal contraception and HIV 
infection is a highly debated one, with the majority of 
experts agreeing that hormonal contraception does not 
increase risk of HIV infection, while the use specifically 
of depot medroxyprogesterone acetate may pose a risk 
of infection [29, 30]. In fact, some studies have shown a 
decreased risk of HIV infection with progesterone only 
pills and combined oral contraception [adjusted hazard 
ratio (HRa)   =   0.86, 95% confidence interval (CI) 0.32, 
1.78] [31]. Of note with our data is that hormonal contra-
ception includes injectable contraception and oral con-
traceptives, which have not shown an increased risk in 
HIV acquisition. One study evaluating the effect of hor-
monal contraception on risk of HSV-2 infection showed 
that injectable contraception did not increase this risk 
[32]. Further studies need to be conducted to confirm 
these findings.
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HSV-2 has emerged as the most prevalent STI, and since 
it is most often asymptomatic, unrecognized and, most 
importantly, incurable, it puts individuals at increased risk 
of acquiring other STIs in addition to HIV. Given the high 
prevalence and incidence of HSV-2 infection reported here, 
screening for symptomatic HSV-2 among high risk popula-
tions should be incorporated into HIV and STI screening 
and treatment packages. Women also need to be encour-
aged to seek treatment for STIs, including symptomatic 
HSV-2. Young women need to be educated about the risk 
of HSV-2 infection, its impact on HIV and STI acquisition, 
and how to prevent HIV and STI acquisition. Despite con-
doms being an effective method of HIV prevention, they 
have only been shown to reduce the transmission of HSV-2 
by 30% [33]. Understanding the prevalence and risk factors 
for common causes of ulcerative genital disease in the gen-
eral population would inform current STI syndromic man-
agement and HIV testing strategies in high HIV prevalence 
regions. Lastly, it is vital that prevention approaches inte-
grate the management of both bacterial and viral STIs for 
young women in these high prevalence regions.
Several limitations need to be considered when 
interpreting our results: this data was taken from the 
responses of women participating in a large, randomized, 
controlled, HIV prevention trial, and therefore may have 
limited representativeness. Women participating in these 
trials often participate because they perceive themselves 
to be at high risk of HIV infection and therefore may not 
represent the general population. The trial protocol also 
limits the sex and age of participants. In addition to this, 
we have not considered the effects of unmeasured char-
acteristics, such as cultural differences (e.g. polygamy), 
poverty, commercial sex and multiple or concurrent sex 
partners in our findings. As this analysis was limited to 
data that was collected as part of an HIV prevention trial, 
the independent variables included are limited. No socio-
economic or behavioral data was collected from the male 
partners of these women. Due to the fact that we could 
not determine the characteristics of women who did not 
present for enrollment into this clinical trial, we must be 
cautious when extrapolating these results to the popula-
tion as a whole. However, these results provide valuable 
information about HIV negative women presenting to 
participate in a HIV prevention trial. These results could 
also indicate that there is a much higher prevalence of 
HSV-2 in the HIV-1 positive population in KZN.
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